Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Cancer Immunol Res. 2019 Oct 15;7(12):2052–2064. doi: 10.1158/2326-6066.CIR-19-0234

Figure 2. Expression and activation of MET is increased in the metastatic population of mouse mammary cancer cells.

Figure 2.

(A) Genes encoding trans-membrane receptors in microarray data sets that were significantly upregulated (logFC >1, dotted red line, P<0.01) in HML2 compared with parental cells. The scale is exponential. (B) A Kaplan-Meier plot of metastasis-free survival of grade III basal type breast cancer patients with high and low expression of MET. In a database established using multiple microarray data sets downloaded from GEO, 146 patient data fitting to the selected parameters (Survival: DMFS, Intrinsic subtype: basal, and Grade: 3) were analyzed using KM Plotter. (C) Relative Met mRNA expression in parental and HML2 cells (n=3). *P<0.05 versus parental, Student’s t test. (D) Representative images of western blots and (E) total and phosphorylated MET and GAB1 relative to β-actin in parental (Prnt) and HML2 cells stimulated with HGF (n=5) at the indicated time in hours (hr) after HGF stimulation. *P<0.05 versus time 0; #P<0.05 versus parental, Student’s t test. Results are mean±SEM.